The 24th Pharma Asia opens on 20 October with more than 230 exhibitors across seven halls and the International Pharma Convention alongside. Here is what is on.
The organiser’s post-show report for the 23rd edition: who came, what exhibitors achieved and how visitors rated the show.
Everything a trade visitor needs for the three days: the E-Pass, opening hours, the seven halls and the convention.
From a trade show to the platform where manufacturers, suppliers, regulators and buyers meet every year — what Pharma Asia does for the industry.
Prices of non-essential medicines were freed in February 2024. Officials now report over 99% availability, while the pricing framework faces a fresh…
Pakistan is at WHO Maturity Level 2 and exports medicines to 52 countries. The health minister expects Level 3 by April 2027.
The July 2026 B2B conference ended with contracts and MoUs focused on local production of vaccines, pharmaceutical raw materials and medical devices.
Regulators now have a global guideline, and continuous lines have shortened release times and approvals. Where the technology stands.
India’s bulk-drug incentive scheme has attracted Rs5,210 crore and is commissioning plants for penicillin G, clavulanic acid and paracetamol’s raw…
The 24th Pharma Asia opens on 20 October with more than 230 exhibitors across seven halls and the International Pharma Convention alongside. Here is…
The organiser’s post-show report for the 23rd edition: who came, what exhibitors achieved and how visitors rated the show.
Everything a trade visitor needs for the three days: the E-Pass, opening hours, the seven halls and the convention.
A quick guide to the 2026 exhibitor list: how many companies are in each hall, where the Chinese exhibitors are, and some of the names to look for.
From a trade show to the platform where manufacturers, suppliers, regulators and buyers meet every year — what Pharma Asia does for the industry.
Former DRAP chiefs, PPMA chairmen, multinational heads and global machinery makers have all spoken at the convention held alongside Pharma Asia.
PPMA chairmen, a DRAP director and company heads on why the exhibition and convention matter for Pakistan’s pharmaceutical sector.
Machinery makers from Germany, Italy, Spain, China and the USA, and exhibitors from 23 countries in 2025: how Pharma Asia connects local plants to…
Prices of non-essential medicines were freed in February 2024. Officials now report over 99% availability, while the pricing framework faces a fresh…
Listed drug makers earned Rs42.2 billion in FY26 on sales of Rs377.9 billion, with gross margins at an all-time high of 42.8%.
The Finance Minister announced the full removal of customs duty on raw materials for locally made medicines, including cancer treatments.
Official figures show a hard year for production and exports — and an ambitious roadmap to $10 billion in exports built on value addition.
Pakistan is at WHO Maturity Level 2 and exports medicines to 52 countries. The health minister expects Level 3 by April 2027.
Pakistan Pharma Vision 2030, exports, PIC/S compliance, AI and track and trace dominated the 2025 convention at Pharma Asia.
DRAP’s SRO 963(I)/2026 requires Data Matrix codes and serial numbers on medicines made or imported from 9 October 2026.
DRAP has made PIC/S GMP its inspection reference and is phasing in the chapters. Pakistan is not yet a PIC/S member. Here is where things stand.
Retail medicine sales rose 14.88% to Rs1.251 trillion in the year to June 2026, while units grew less than 1%. National companies hold nearly 80% of…
With crossings to Pakistan’s largest medicine market shut since October 2025, exports fell 27.67% in July–February FY26. What exporters are facing.
The July 2026 B2B conference ended with contracts and MoUs focused on local production of vaccines, pharmaceutical raw materials and medical devices.
Pakistan’s first vaccine policy starts with fill-and-finish and aims for full production. With Gavi support ending in 2031, the clock is running.
Zavod Medsintez and Genetics Pharmaceuticals plan an aseptic filling plant by 2028 and insulin API production by 2031.
A May 2026 summit set a goal of local manufacture of at least 30% of medical devices by 2030, with a proposed Rs1 billion R&D fund.
Regulators now have a global guideline, and continuous lines have shortened release times and approvals. Where the technology stands.
Eli Lilly credits AI with producing more medicine than it otherwise could; agentic AI is halving deviation investigations. What is real, and what it…
Europe’s revised sterile-manufacturing rules require a contamination control strategy and favour barrier technology. Why it matters beyond Europe.
Printing tablets layer by layer lets designers control how a drug is released. A look at the technology and how far it has come.
India’s bulk-drug incentive scheme has attracted Rs5,210 crore and is commissioning plants for penicillin G, clavulanic acid and paracetamol’s raw…
Cost, scale and concentration make China central to generic APIs. Tariffs, rebates and quality enforcement are changing the picture.
Biocatalysis and greener solvents cut steps and waste. The world’s leading drug makers are investing — and the tools are openly shared.
New excipients can enable abuse-deterrent and better-absorbed medicines. Why regulators created a special review route, and what it means for…
Pharma Asia
20–22 October 2026
Karachi Expo Centre, Karachi
The show is on now
Pharma Asia in numbers — the December 2025 Karachi edition
